Melanoma research gets a funding boost from NHMRC
9 December 2016
Research projects led by Melanoma Institute Australia (MIA) have been awarded almost $6 million in the latest National Health and Medical Research Council (NHMRC) funding round which will enable vital progression of research into melanoma prevention and treatment. Projects led by MIA researchers have been awarded the highly competitive funding:
- Professor Georgina Long (MIA and The University of Sydney) received a Practitioner Fellowship (5 years) to investigate the underlying biology of patients’ responses to treatment. By understanding why some patients respond well to therapies when others develop resistance will help us develop tests to ensure the best possible treatment is given to each individual patient. In addition, it will also help identify the ideal drug therapy combinations to improve patient outcomes further or prevent metastatic melanoma altogether.
- Professor Nicholas Hayward (MIA and QIMR Berghofer) received a Research Fellowship (3 years) to investigate genetic predisposition to melanoma in the general population and predisposed families, and the genes involved in traits underlying melanoma development. He was also awarded a Project Grant (5 years) to conduct a comprehensive genetic analysis of acral melanoma to ultimately identify new drug targets to treat this disease. Although an uncommon subtype of melanoma, acral melanoma has a bad prognosis and has been poorly characterised at the molecular level.
- Professor Helen Rizos (MIA and Macquarie University) received two Project Grants to investigate the cell biology of melanoma. These project grants involved a team of chief investigators from MIA, who have collaborated on melanoma response and resistance for many years, including Professor Richard Kefford, Professor Georgina Long, Dr Matteo Carlino, Dr Alexander Menzies and Dr Xu Dong Zhang, and new collaborator Professor Barbara Fazekas de St Groth. The first Project Grant (4 years) will be used to investigate the mechanisms of response and resistance to combination immunotherapies in order to enhance the duration and rate of patient response. The second Project Grant (4 years) will use tumour samples of patients who have developed resistance to immunotherapies to determine the underlying mechanisms involved. This information will accelerate the identification of new combination therapies to improve patient outcomes.
- Associate Professor Anne Cust (MIA and The University of Sydney) was awarded a 4-year Project Grant to improve skin cancer prevention. Her research will evaluate whether they can improve skin cancer prevention behaviours by giving personalised information about melanoma genetic risk. They will also explore the psycho-social, ethical and economic implications of receiving this information, with the ultimate aim to positively influence the future of skin cancer prevention in Australia.
To date, the 2016 NHMRC Grant Application Round has resulted in the commitment of more than $703 million to fund health and medical research across Australia.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.